- Home
- CATO vs IXHL Comparison
CATO vs IXHL Comparison
Compare CATO & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CATO | IXHL |
|---|---|---|
| Founded | 1946 | 2001 |
| Country | United States | Australia |
| Employees | 7000 | N/A |
| Industry | Clothing/Shoe/Accessory Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.0M | 97.6M |
| IPO Year | 1994 | 2024 |
Fundamental Metrics
Financial Performance| Metric | CATO | IXHL |
|---|---|---|
| Price | $2.98 | $3.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 49.1K | ★ 4.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.09 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $649,806,000.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.16 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.19 | $0.11 |
| 52 Week High | $4.92 | $6.39 |
Technical Indicators
Market Signals| Indicator | CATO | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 45.19 | 56.41 |
| Support Level | $2.81 | $0.31 |
| Resistance Level | $3.22 | $5.17 |
| Average True Range (ATR) | 0.18 | 0.51 |
| MACD | -0.00 | 0.09 |
| Stochastic Oscillator | 17.31 | 49.82 |
Price Performance
Historical ComparisonAbout CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.